$ News

Durect: Q2 Earnings Snapshot

DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health

Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment

Bausch Health to Acquire Nasdaq-listed Durect for US$63 Million

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

Durect: Q1 Earnings Snapshot

DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn Situation

Q4 2024 DURECT Corp Earnings Call

Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges

Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates

Durect: Q4 Earnings Snapshot

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates

DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

Durect (DRRX) Upgraded to Strong Buy: Here's Why

Durect (DRRX) Upgraded to Buy: Here's What You Should Know